NCT01519687View on ClinicalTrials.gov

Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
HyperuricemiaGout
Interventions
DRUG

levotofisopam

50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7

Trial Locations (1)

27720

RECRUITING

Duke Clinical Research Unit (DCRU), Durham

Sponsors

Lead Sponsor

Pharmos
All Listed Sponsors
lead

Pharmos

INDUSTRY